Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer.

Bibliographic Details
Title:	Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer.
Authors:	Milgram, Benjamin C., Borrelli, Deanna R., Brooijmans, Natasja, Henderson, Jack A., Hilbert, Brendan J., Huff, Michael R., Ito, Takahiro, Jackson, Erica L., Jonsson, Philip, Ladd, Brendon, O'Hearn, Erin L., Pagliarini, Raymond A., Roberts, Simon A., Ronseaux, Sébastien, Stuart, Darrin D., Wang, Weixue, Guzman-Perez, Angel
Source:	Journal of Medicinal Chemistry; 2/13/2025, Vol. 68 Issue 3, p2403-2421, 19p
Database:	Supplemental Index

More Details
ISSN:	00222623
DOI:	10.1021/acs.jmedchem.4c02377
Published in:	Journal of Medicinal Chemistry
Language:	English